Citi Appointed Depositary Bank for LianBio’s Sponsored ADR Program

Citi’s Issuer Services, acting through Citibank, N.A., has been appointed as the depositary bank by LianBio for its American Depositary Receipt (ADR) program.

The LianBio program was established in connection with an approximately $325 million initial public offering of its American Depositary Shares (ADSs), priced at $16.00 per ADS. The ADSs are listed on the Nasdaq Global Market, under the ticker symbol “LIAN”. Each ADS represents one ordinary share of LianBio.

“Citi is committed to providing LianBio and its investors with the highest quality ADR services, and our selection as depositary bank for the company’s ADR program underscores the depth and breadth of Citi’s cross-border capabilities,” said Dirk Jones, Global Head of Issuer Services at Citi.

Citi is a leading provider of depositary receipt services. With depositary receipt programs in 67 markets, spanning equity and fixed-income products, Citi leverages its global network to provide cross-border capital market access to issuers, intermediaries and investors.

For more information about Citi’s Depositary Receipt Services, please visit www.citi.com/dr.

Citi

Citi, the leading global bank, has approximately 200 million customer accounts and does business in more than 160 countries and jurisdictions. Citi provides consumers, corporations, governments and institutions with a broad range of financial products and services, including consumer banking and credit, corporate and investment banking, securities brokerage, transaction services, and wealth management.

Additional information may be found at www.citigroup.com | Twitter: @Citi | YouTube: www.youtube.com/citi | Blog: http://blog.citigroup.com | Facebook: www.facebook.com/citi | LinkedIn: www.linkedin.com/company/citi

View source version on businesswire.com: https://www.businesswire.com/news/home/20211115005280/en/